Study of Lanreotide Autogel 120 mg in Patients With Non-functioning Entero- Pancreatic Endocrine Tumour

PHASE3CompletedINTERVENTIONAL
Enrollment

89

Participants

Timeline

Start Date

February 28, 2009

Primary Completion Date

December 31, 2015

Study Completion Date

December 31, 2015

Conditions
Non Functioning Entero-pancreatic Endocrine Tumour
Interventions
DRUG

lanreotide (Autogel formulation)

Autogel 120 mg

Trial Locations (25)

51092

Hôpital R. Debré, Reims

59020

CAC Oscar Lambret, Lille

69437

Hôpital Edouard Herriot, Lyon

90048

Cedars-Sinai Outpatient Cancer Center, Los Angeles

92118

Hôpital Beaujon, Clichy

21287-4606

The Johns Hopkins Hospital, Baltimore

Unknown

UZ Antwerpen, Antwerp

UCL Saint Luc, Brussels

Fakultni nemocnice Na Bulovce, Prague

General faculty, Prague

Centro di Refierimiento Oncologica, Aviano

INSCT, Milan

University of Naples, Naples

Azienda San Giovanni Battista, Torino

"Centrum Diagnostyczno-Lecznicze Gammed", Warsaw

Zaklad Diagnosttyki Radiologicznej, Centralny Szpital Klincny, Warsaw

Narodny onkologicky ustav, Bratislava

Hospital Vall d'Hebron, Barcelona

Institut Catala Oncologia, Barcelona

University Hospital Wales, Cardiff

Western General Hospital, Edinburgh

Beatson West of Scotland Cancer Centre, Glasgow

St James Hospital, Leeds

Royal Free Hospital, London

QMC, Nottingham

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Ipsen

INDUSTRY

NCT00842348 - Study of Lanreotide Autogel 120 mg in Patients With Non-functioning Entero- Pancreatic Endocrine Tumour | Biotech Hunter | Biotech Hunter